generation run 2026-05-09
58 min completedmodel pipeline-v5plan not recordedrun/7a333924…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- structural_inference
- safety_data_unverified
- sparse_evidence
- reviewer_action_needed
Reproduce
- inputs
- 19 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
22 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubMed | metizolam detection urine metabolism analytical | 2 | — | — |
| 2 | PubMed | PMID 31971477 | 1 | 1 | Comparative potency analysis and user-reported effects of metizolam. |
| 3 | PubMed | PMID 30348014 | 1 | 1 | Clinical toxicology data including metizolam intoxication cases. |
| 4 | OpenAlex | metizolam designer benzodiazepine | 40 | 7 | All directly relevant to metizolam or closely related designer BZDs with comparative data. |
| 5 | PubChem | metizolam | 1 | 1 | Chemical identity confirmation for all structural data fields in the article. |
| 6 | PubMed · absence | metizolam thienodiazepine pharmacology | 0 | — | — |
| 7 | ClinicalTrials.gov · absence | metizolam | 0 | — | — |
| 8 | PubMed | etizolam pharmacokinetics half-life human | 5 | 4 | Etizolam is the closest well-studied structural analog of metizolam (differing by one methyl group). CYP enzyme data relevant to inferring metizolam metabolism. |
| 9 | PubMed | PMID 27671107 | 1 | 1 | Primary human self-administration study of metizolam — key pharmacokinetic and metabolic data. |
| 10 | Crossref | DOI 10.1016/j.scijus.2017.12.004 | 1 | 1 | QSAR-derived GABA-A binding estimates for metizolam |
| 11 | WebSearch | metizolam UK Class C Misuse of Drugs Act scheduling 2017 | 10 | 2 | Primary UK legal authority for metizolam scheduling |
| 12 | OpenAlex | QSAR GABA-A benzodiazepine receptor binding new psychoactive substances | 8 | 2 | Greenblatt review provides clinical context; Waters QSAR paper key for binding affinity inference |
| 13 | WebSearch | metizolam Australia scheduling USA analog act desmethyletizolam | 10 | 1 | Legal status across additional jurisdictions |
| 14 | WebSearch | metizolam legal status scheduling UK USA Europe controlled substance | 10 | 4 | Legal status by jurisdiction required for article |
| 15 | PubMed | PMID 30730611 Greenblatt designer benzodiazepines | 1 | 1 | Provides clinical pharmacology context for metizolam as a designer BZD |
| 16 | WebFetch | psychonautwiki metizolam article | 1 | 1 | Community reference for effects profile (insufficient verification level) |
| 17 | Multiple | metizolam chemical identity verification | 3 | 1 | Chemical identity data verification complete |
| 18 | PubMed | benzodiazepine alcohol ethanol CNS depression pharmacodynamic interaction | 6 | 1 | Flumazenil use in BZD overdose relevant to emergency management of metizolam intoxication |
| 19 | WebSearch | metizolam UK Class C Misuse of Drugs Act scheduling 2017 | 10 | 2 | UK legal authority confirmation |
| 20 | WebSearch/WebFetch | metizolam history patent first appearance research chemical market | 10 | 3 | Historical context for metizolam origin and emergence |
| 21 | WebSearch | metizolam overdose case report intoxication hospital emergency | 10 | — | — |
| 22 | OpenAlex | etizolam pharmacology GABA binding affinity benzodiazepine receptor | 8 | 2 | Mechanism of action and GABA-A receptor pharmacology relevant to thienodiazepines |
66 claims by section — every cited sentence, checked against its source
safety19 · 10 ok
Claim in safety — inconclusiveinconclusiveworking →
Class-level inference supports a large therapeutic index for benzodiazepines and thienodiazepines when used alone — mortality from oral benzodiazepine overdose in isolation is rare.supported
Mortality/morbidity almost exclusively in polysubstance use. cpdd.667
Four confirmed metizolam intoxication cases were reported in the Swedish STRIDA project (2012–2016)supported
Metizolam confirmed in 4 cases. (2012-2016) 15563650.2018.1506130
Across the broader STRIDA dataset of 217 NPS benzodiazepine cases, CNS depression was the most prominent clinical sign, 89% of cases involved concurrent polysubstance use, and all patients exposed to NPS benzodiazepines alone responded to flumazenil (GABA-A antagonist), confirming the benzodiazepine mechanism.partially supported
15 different NPS BZDs confirmed in 217/1913 cases (2012-2016). CNS depression most prominent; flumazenil-responsive. 15563650.2018.1506130
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Designer benzodiazepines including metizolam have been identified as agents of drug-facilitated sexual assault (DFSA) due to their amnestic and sedative properties.supported
DBZDs are active at low doses, fast onset, easily administered orally - ideal DFSA candidates. bkac017
Benzodiazepine tolerance develops through GABA-A receptor downregulation and compensatory subunit composition changessupported
Review of GABAA receptor subtype contributions to benzodiazepine addiction, tolerance, and therapeutic effects. ndt.s164307
Physical dependence develops with regular benzodiazepine use, potentially within weeks of daily administration. etizolam — the closest structural analog — has documented case reports of dependence despite initial marketing claims of lower dependence liabilitysupported
Case of etizolam dependence in young male with social anxiety and depression. Highlights dependence potential comparable to benzodiazepines despite claims of lower liability. 0253-7613.144943
Claim in safety — inconclusiveinconclusiveworking →
CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, HIV protease inhibitors) may elevate metizolam plasma concentrations by reducing hepatic clearance — an interaction demonstrated with itraconazole and etizolam. CYP inducers (carbamazepine, rifampicin, phenytoin) may accelerate metizolam metabolism and reduce clinical effects, as demonstrated with carbamazepine and etizolam.partially supported
Itraconazole inhibited etizolam metabolism, confirming CYP3A4 involvement. pmid:15232663
CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, HIV protease inhibitors) may elevate metizolam plasma concentrations by reducing hepatic clearance — an interaction demonstrated with itraconazole and etizolam. CYP inducers (carbamazepine, rifampicin, phenytoin) may accelerate metizolam metabolism and reduce clinical effects, as demonstrated with carbamazepine and etizolam.partially supported
Carbamazepine induced etizolam metabolism via CYP induction. pmid:15776275
Flumazenil considerations: In documented NPS benzodiazepine intoxications, flumazenil reversed CNS depressionsupported
CNS depression most prominent; some ICU cases; flumazenil-responsive. 15563650.2018.1506130
However, flumazenil carries its own risks — a meta-analysis of 13 RCTs found significantly increased adverse events versus placebo (RR 2.85), including supraventricular arrhythmia and convulsionssupported
Meta-analysis of 13 RCTs (994 patients). Flumazenil group had significantly more AEs than placebo (2.85x risk). SAEs included supraventricular arrhythmia and convulsions. bcpt.12434
pharmacology14 · 8 ok
Claim in pharmacology — inconclusiveinconclusiveworking →
Metizolam functions as a positive allosteric modulator (PAM) of the GABA-A receptor, potentiating the effect of endogenous GABA at the benzodiazepine binding site of the GABA-A receptor complexsupported
Class-inference approach. Flumazenil-responsive. cpdd.667
Waters et al. applied a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding for emerging benzodiazepines including metizolamsupported
QSAR model to predict GABA-A receptor binding potency of newly emerging designer benzodiazepines based on chemical structure. Includes metizolam in analysis. j.scijus.2017.12.004
Claim in pharmacology — inconclusiveinconclusiveworking →
The sole published human pharmacokinetic data derive from Kintz et al., who conducted a controlled self-administration study in one adult male volunteer (age 54) following a single 2 mg oral dose of metizolam.supported
Metizolam 2 mg oral dose to 54-year-old volunteer. dta.2099
By structural analogy to etizolam, which achieves Tmax of 0.5–2 hours and demonstrates rapid absorption after oral administration, metizolam is expected to reach peak plasma concentrations within 1–2 hours of oral ingestionsupported
Etizolam PK: Tmax 0.5-2h. pmid:2065698
Claim in pharmacology — inconclusiveinconclusiveworking →
By analogy to etizolam, CYP3A4 and CYP2C19 are the likely primary metabolizing enzymes.supported
Itraconazole inhibited etizolam metabolism, confirming CYP3A4 involvement. pmid:15232663
By analogy to etizolam, CYP3A4 and CYP2C19 are the likely primary metabolizing enzymes.supported
CYP2C19 polymorphism affects etizolam PK/PD. pmid:16261363
Approximately 0.3% of the administered dose was excreted as unchanged metizolam in urine within the first 24 hours, consistent with extensive hepatic metabolismsupported
~0.3% excreted unchanged in 24h. dta.2099
For reference, etizolam has a plasma half-life of approximately 3.4 hours, with its primary active metabolite alpha-hydroxyetizolam showing a half-life of approximately 8.2 hours.supported
t1/2 ~3.4h; alpha-hydroxyetizolam metabolite t1/2 ~8.2h. pmid:2065698
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
summary7 · 3 ok
Comparative analysis of user-submitted trip reports ranks metizolam among the least potent designer benzodiazepines, grouped with deschloroetizolam, nifoxipam, and pyrazolamsupported
Metizolam ranked among least potent DBZDs alongside deschloroetizolam, nifoxipam, pyrazolam. 0269881119901096
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
As a thienotriazolodiazepine, metizolam is presumed to potentiate GABAergic neurotransmission at the benzodiazepine binding site of the GABA-A receptor complex — no substance-specific binding affinity data (Ki or EC50) have been publishedsupported
No systematic pharmacodynamic or receptor binding data exists for designer BZDs. Class-inference approach. Flumazenil-responsive. cpdd.667
Claim in summary — inconclusiveinconclusiveworking →
The compound's pharmacokinetic parameters — plasma half-life, bioavailability, volume of distribution — remain uncharacterized in humans; only a 46-hour urinary detection window and three hydroxylated metabolites have been identified from a single-subject study.supported
Detectable in hydrolyzed urine to 46h (<11 ng/mL). Three mono-hydroxylated metabolites: M1 (main), M2, M3. dta.2099
history6 · 3 ok
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
In the peer-reviewed literature, metizolam first appears in the Swedish STRIDA project dataset, where 4 confirmed intoxication cases involving metizolam were reported between 2012 and 2016, and in the controlled self-administration study by Kintz et al., which documents the first and only published human pharmacokinetic data for the compoundsupported
Metizolam confirmed in 4 cases. (2012-2016) 15563650.2018.1506130
In the peer-reviewed literature, metizolam first appears in the Swedish STRIDA project dataset, where 4 confirmed intoxication cases involving metizolam were reported between 2012 and 2016, and in the controlled self-administration study by Kintz et al., which documents the first and only published human pharmacokinetic data for the compoundsupported
Metizolam 2 mg oral dose to 54-year-old volunteer. Detectable in hydrolyzed urine to 46h. dta.2099
By 2020, 29 designer benzodiazepines had been notified to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).supported
29 designer BZDs notified to EMCDDA. 1570159x18666200110121333
Claim in history — inconclusiveinconclusiveworking →
pharmacokinetic-detail6 · 5 ok
Three metabolites (M1, M2, M3) were identified via human liver microsome incubation, with M1 (ethyl-hydroxylated metizolam) as the predominant productsupported
Three mono-hydroxylated metabolites: M1 (main, hydroxylation of 2-ethyl moiety), M2 (N-hydroxy), M3. dta.2099
By analogy, etizolam's primary metabolite alpha-hydroxyetizolam retains pharmacological activity and contributes to the clinical duration of effectsupported
t1/2 ~3.4h; alpha-hydroxyetizolam metabolite t1/2 ~8.2h. pmid:2065698
CYP3A4 inhibitors (itraconazole, ketoconazole): Itraconazole significantly inhibited etizolam metabolism in a controlled human study, increasing plasma exposure. An analogous interaction is expected with metizolam.supported
Itraconazole inhibited etizolam metabolism, confirming CYP3A4 involvement. pmid:15232663
CYP inducers (carbamazepine, rifampicin): Carbamazepine induced etizolam metabolism, reducing plasma levels and clinical effects. Metizolam clearance may be similarly accelerated.supported
Carbamazepine induced etizolam metabolism via CYP induction. pmid:15776275
CYP2C19 polymorphisms: Etizolam pharmacokinetics vary with CYP2C19 genotype, with poor metabolizers showing higher plasma exposure and prolonged effects. CYP2C19 poor metabolizers may experience enhanced or prolonged effects with metizolam, though this has not been studied.supported
CYP2C19 polymorphism affects etizolam PK/PD. pmid:16261363
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
chemistry3 · 0 ok
clinical-evidence3 · 3 ok
The only published controlled human data derive from a single self-administration pharmacokinetic study in one healthy male volunteer (age 54) who received a 2 mg oral dosesupported
Metizolam 2 mg oral dose to 54-year-old volunteer. dta.2099
Clinical toxicology data are limited to 4 confirmed intoxication cases reported through the Swedish STRIDA project between 2012 and 2016supported
Metizolam confirmed in 4 cases. (2012-2016) 15563650.2018.1506130
Across the broader STRIDA dataset of 217 NPS benzodiazepine intoxication cases, CNS depression was the most prominent clinical sign, and all patients exposed to NPS benzodiazepines alone responded to flumazenil.supported
15 different NPS BZDs confirmed in 217/1913 cases (2012-2016). CNS depression most prominent; flumazenil-responsive. 15563650.2018.1506130
neuroscience3 · 3 ok
Cortical suppression — Reduced cortical excitability mediates the sedative, amnestic, and anticonvulsant effects. Alpha-1 subunit-containing GABA-A receptors, densely expressed in cortical and cerebellar regions, are the primary mediators of sedation and amnesia.supported
Review of GABAA receptor subtype contributions to benzodiazepine addiction, tolerance, and therapeutic effects. ndt.s164307
Amygdala inhibition — Enhanced GABAergic tone in the basolateral amygdala reduces fear-conditioned responses and anxiety. Alpha-2 and alpha-3 subunit-containing receptors in limbic circuits mediate anxiolytic effects with less sedation than alpha-1 activation.supported
Review of GABAA receptor subtype contributions to benzodiazepine addiction, tolerance, and therapeutic effects. ndt.s164307
Chronic benzodiazepine exposure induces compensatory neuroadaptation: GABA-A receptor downregulation, subunit composition changes (particularly reduced alpha-1 and increased alpha-4/delta subunit expression), and glutamatergic upregulationsupported
Review of GABAA receptor subtype contributions to benzodiazepine addiction, tolerance, and therapeutic effects. ndt.s164307
receptor-pharmacology3 · 2 ok
Waters et al. included metizolam in a QSAR model predicting GABA-A receptor binding affinity for emerging benzodiazepines, but the specific predicted binding value was not reported in the available abstractsupported
QSAR model to predict GABA-A receptor binding potency of newly emerging designer benzodiazepines based on chemical structure. Includes metizolam in analysis. j.scijus.2017.12.004
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Alpha-1 subunit-mediated effects (sedation, amnesia, anticonvulsant activity) and alpha-2/alpha-3-mediated effects (anxiolysis, muscle relaxation) are both anticipated based on class pharmacologysupported
Review of GABAA receptor subtype contributions to benzodiazepine addiction, tolerance, and therapeutic effects. ndt.s164307
comparative-pharmacology1 · 0 ok
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
effects-overview1 · 1 ok
Relative to etizolam, its N-methylated parent compound, metizolam is reported as less potent and less euphoric in community comparative assessmentssupported
Trip reports of 10 designer BZDs analyzed. Metizolam ranked among least potent DBZDs alongside deschloroetizolam, nifoxipam, pyrazolam. 0269881119901096